Director Of Phathom Pharmaceuticals Makes $587 Thousand Sale
David A Socks, Director at Phathom Pharmaceuticals (NASDAQ:PHAT), made a large insider sell on September 22, according to a new SEC filing.
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
Phathom Pharmaceuticals Q2 EPS $(1.00) Down From $(0.64) YoY
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.00) per share. This is a 56.25 percent decrease over losses of $(0.64) per share from the same period last year.
